AC Immune SA (ACIU) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AC Immune SA (ACIU) has outperformed Upstream Bio (UPB) over the past year, losing 27.6% versus a loss of 76.0%. AC Immune SA is the larger company by market cap ($253.5 million vs $249.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | UPB |
|---|---|---|
| Share price | $2.55 | $4.55 |
| Market cap | $253.54M | $249.21M |
| 1-day change | -0.78% | -1.30% |
| YTD return | -18.79% | -83.24% |
| 1-year return | -27.56% | -75.95% |
| 5-year return | -58.74% | — |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $33.68 |
| 52-week low | $2.10 | $4.37 |
| Distance from 52-week high | -36.25% | -86.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +234.12% | +584.40% |
| Average volume | 202.76K | 610.08K |
| Shares outstanding | 99.43M | 54.77M |
| Employees | 90 | 75 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed UPB by 48.4 percentage points over the past year.
- The two companies sit in different sectors: AC Immune SA in Health Care and Upstream Bio in Healthcare.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
ACIU vs UPB FAQ
Which is bigger, AC Immune SA or Upstream Bio?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $249.21M for Upstream Bio (UPB).
Which stock has performed better over the past year, ACIU or UPB?
ACIU returned -27.56% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Upstream Bio in the same industry?
No. AC Immune SA is in the Health Care sector, while Upstream Bio is in Healthcare.